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ScienceDirectSynthetic biology is opening up new opportunities for the
sustainable and efficient production of valuable chemicals in
engineered microbial factories. Here we review the application
of synthetic biology approaches to the engineering of
monoterpene/monoterpenoid production, highlighting the
discovery of novel catalytic building blocks, their accelerated
assembly into functional pathways, general strategies for
product diversification, and new methods for the optimization
of productivity to economically viable levels. Together, these
emerging tools allow the rapid creation of microbial production
systems for a wide range of monoterpenes and their derivatives
for a diversity of industrial applications.
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Synthetic biology for the production of
monoterpenes and monoterpenoids
Synthetic biology is a powerful combination of multiple
scientific disciplines, including biochemistry, molecular
biology, systems biology, computational biology, and
engineering, for the controlled design and construction
of biological systems with new functionalities. One eco-
nomically attractive application is the development of
microbial factories for the biosynthesis of high-value
chemical commodities such as pharmaceuticals, flavours,
fragrances, fuels and many more. In order to achieve
optimal biosynthetic production of these molecules,
genes encoding enzymes involved in a desired biochemi-
cal pathway are collected from various source organisms
(microbes, plants and fungi), modified and improved,
and finally introduced into engineered production hostswww.sciencedirect.com (chassis) that are most suitable for production. The most
famous synthetic biology example of high-value chemical
production is artemisinic acid, the precursor of the anti-
malarial drug arteminisin, which was produced in engi-
neered Escherichia coli and baker’s yeast, Saccharomyces
cerevisiae, reaching economically viable production levels
after 10 years of iterative optimization [1,2].
Artemisinic acid is just one of thousands of potentially
high-value terpenoids, and synthetic biology approaches
towards versatile and robust biosynthetic production of
additional members of this highly diverse class of chemi-
cals have attracted considerable interest in recent years.
Here, we specifically discuss recent developments towards
a general synthetic biology toolbox for the production of
monoterpenes/monoterpenoids, a particularly interesting
subset of this family of molecules, with over 55,000 differ-
ent compounds and many applications (e.g. as drugs, food
flavourings, fragrances, biofuels and cleaning agents) [3].
Traditionally, monoterpenes and their derivatives are
extracted from natural sources (generally plants), but this
extraction process can be low yielding, costly, and some-
times highly dependent on raw material availability [4]; a
synthetic biology approach to their synthesis provides a
sustainable route to production and opens new possibilities
for diversification and discovery.
The terpene precursor pathways
The biosynthesis of all terpenes is dependent on the two
(C5) isoprene precursors isopentenyl pyrophosphate
(IPP) and dimethylallyl pyrophosphate (DMAPP), which
are synthesized via either the methylerythritol 4-phos-
phate (MEP) pathway, also known as the 1-deoxy-D-
xylulose5-phosphate (DXP) pathway, or the mevalo-
nate-dependent (MVA) pathway (Figure 1). IPP and
DMAPP are condensed to form the terpene pre-cursors,
with the order of the terpene being defined by the
number of isoprene units incorporated (monoterpenes,
C10; sesquiterpenes, C15 etc.; and so on). The universal
precursor of monoterpenes is geranyl pyrophosphate
(GPP), combining two C5 units, which is then further
processed by monoterpene synthases/cyclases (mTS/C)
to produce a vast array of chemical structures [5,6].
All organisms possess at least one route towards terpenoid
production, either an MVA or an MEP pathway. The
predominant source of monoterpenes/monoterpenoids
is plants, which possess both a cytosolic MVA and aCurrent Opinion in Chemical Biology 2016, 34:37–43
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An overview of monoterpene/monoterpenoid production pathways.plastidial MEP pathway [7]. Typically, yeast, animals and
archaea use the MVA pathway, whereas bacteria predom-
inantly employ the MEP pathway; however, some species
of bacteria can use an MVA pathway, whilst others use
both [8].
Early engineering efforts to create monoterpene/oid and
sesquiterpene/oid production systems in bacteria aimed
to improve the availability of precursors by increasing the
intracellular production of IPP and DMAPP [6]. This wasCurrent Opinion in Chemical Biology 2016, 34:37–43 achieved by the insertion of the 1-deoxy-D-xyulose-5-
phosphate synthase (DXS) and IPP isomerase (IPPHp)
genes, responsible for the expression of key enzymes in
the DXP/MEP pathway, thereby supplementing the en-
dogenous E. coli pathway. When these biosynthetic path-
ways were expressed alongside monoterpene and
sesquiterpene synthases, initial titres were in the low
mg/L range. The subsequent efforts to improve the
terpene titres have been extensively reviewed by Paddon
and Keasling [1].www.sciencedirect.com
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Table 1
Diversity of monoterpene/monoterpenoid production strains engineered to date.
Monoterpenoid
product
Host Pre-cursor
pathways
mTS/C mTS/C
source
Maximum
titre (mg/L)
Volumetric
productivity
(mg/L/day)
Reference
Limonene E. coli MEP, GPPS Limonene synthase Mentha spicata 35.8 11.9 Du et al., 2014 [16]
E. coli MVA, GPPS Limonene synthase Abies grandis 605.0 201.7 Alonso-Gutierrez et al.,
2015 [12]
S. cerevisiae MVA, ERG20 Limonene synthase Citrus  limon 0.5 0.2 Jongedijk et al. (2015) [48]
a-Pinene E. coli MVA, GPPS2 Pinene synthase Abes grandis 32.4 10.8 Sarria et al. (2014) [49]
C. glutamicum MEP, IDI, GPPS Pinene synthase Pinus taeda 0.176 0.088 Kang et al., 2014 [30]
b-Pinene E. coli MVA, GPPS2 Pinene synthase Abies grandis 32.4 10.8 Sarria et al. (2014) [49]
C. glutamicum MEP, IDI, GPPS Pinene synthase Abies grandis 0.165 0.055 Kang et al., 2014 [30]
Myrcene E. coli MVA, GPPS Myrcene synthase Quercus ilex 58.2 19.4 Kim et al., 2015 [14]
Sabinene E. coli MVA, GPPS2 Sabinene synthase Salvia pomifera 82.2 82.2 Zhang et al. (2014) [50]
S. cerevisiae MVA, ERG20 Sabinene synthase Salvia pomifera 17.5 n/a Ignea et al., 2014 [20]
Geraniol E. coli MVA, GPPS Geraniol synthase Ocimum
basilicum
182.5 91.3 Zhou et al. (2014) [51]
Linalool S. cerevisiae MVA Linalool synthase Lavandula
angustifolia
0.095 n/a Amiri et al., 2015 [19]
Cineole S. cerevisiae MVA, ERG20, IDI Cineole synthase Salvia fruticosa 1100 57.9 Ignea et al., 2011 [21]
3-Carene E. coli MEP, GPPS 3-Carene cyclase Picea abies 0.003* 0.01* Reiling et al., 2004 [6]
* For 3-carene, the maximum titre and volumetric productivity are indicated in mg/L/OD600 and mg/L/day/OD600, respectively.Monoterpene synthases
Monoterpene synthases/cyclases (mTS/C) produce a
plethora of chemicals from a single substrate (GPP)
and provide a powerful opportunity for the production
of diverse chemical libraries (Figure 1). They are a metal-
dependent family of enzymes that typically catalyse the
cyclisation of GPP via an a-terpinyl cation intermediate,
or elimination and addition reactions from the linear
geranyl cation intermediate, resulting in a diverse selec-
tion of monoterpene products (Figure 1). mTS/C are most
commonly found in plants; however, recent genome
mining efforts have demonstrated that terpene synthases
also commonly occur in bacteria [9,10].
Synthetic biology production of
monoterpenes/monoterpenoids
Over the last decade, numerous monoterpenes/monoter-
penoids have been produced by engineered bacteria and
yeast. A specialised limonene (and perillyl alcohol) pro-
duction system was created in E. coli by introducing
heterologous, codon-optimized, Staphylococcus aureus
and S. cerevisiae MVA pathway genes into E. coli alongside
the Abies grandis GPP synthase and Mentha spicata limo-
nene synthase genes. Optimization of gene regulation
and growth conditions resulted in a limonene titre of
400 mg/L [11]. Following this work, principal compo-
nent analysis (PCA) was used in an effort to further
improve the previously obtained limonene titres [12].
The authors of this study created a total of 27 production
‘scenarios’, in which the nine enzymes of the MVA
pathway were present in different copy numbers under
different promoters, and testing these in three different
cell densities and three inducer concentrations. Proteo-
mics (LC–MS/MS) and limonene production (GC–MS)www.sciencedirect.com data were obtained for each of these scenarios. Surpris-
ingly, no single enzyme level showed a clear correlation
with improved production, as tested by univariate statis-
tics. However, the application of PCA, a multivariate
statistical method, allowed the identification of combina-
tions of proteins that needed to be optimized in order to
achieve improved production. The results indicated that
low and balanced expression of the early steps of precur-
sor production, alongside an overexpression of limonene
synthase would yield the optimal product titre. This was
subsequently confirmed by constructing a production
strain with these characteristics, which attained a maximal
titre of 605 mg/L of limonene, a 40% improvement over
the original pathway [12] (Table 1).
The recent development of improved combinatorial de-
sign approaches for the assembly and characterization of
large multi-gene operons further facilitates optimization
strategies [13–15]. Using these approaches, which depend
on the design of standardized re-usable bioparts and
improved method for their rapid assembly, it is possible
to quickly test a large number of pathway variants that
differ, for example, in their promoter strengths, ribosomal
binding sites, gene order, orientation and operon struc-
ture, to identify the most productive combination.
Alternative strategies in E. coli focussed on the MEP
pathway, over-expressing the dxs and isopentenyl diphos-
phate isomerase (idi) genes, which had previously been
identified as encoding rate limiting enzymes in the en-
dogenous MEP E. coli pathway; however, the resulting
strains provided a poor titre of 35.8 mg/L limonene [16].
Willrodt and colleagues subsequently demonstrated that
the choice of bacterial production chassis, feedstock
and fermentation approach have a major influence onCurrent Opinion in Chemical Biology 2016, 34:37–43
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increased production of limonene in E. coli grown on
glycerol in minimal media, due to a prolonged growth and
production phase [17]. Moreover, they were able to
further improve limonene production by limiting magne-
sium sulphate availability [18]: in these nutrient-limited
minimal media the cells enter a ‘resting’ state, in which
cellular resources are no longer consumed for biomass and
by-product formation, thereby increasing resource avail-
ability for limonene production.
While most of the synthetic biology of monoterpenes so
far has focused on limonene production as a test case, E.
coli has also been engineered to produce a variety of other
monoterpenes, including a-pinene, myrcene, geraniol
and sabinene, by the assembly and optimization of bio-
synthetic pathways containing a heterologous MVA or
MEP pathway, a GPP synthase and the monoterpene
synthase of interest (Table 1).
As an alternative to E. coli, yeast has proven to be a
successful chassis for monoterpene/monoterpenoid pro-
duction, with strains capable of sabinene, limonene,
linalool [19] and cineole production, obtained to date
(Table 1). In the case of sabinene and limonene produc-
tion, an engineered farnesyl pyrophosphate synthase
(FPP synthase) Erg20 enzyme functioning as a GPP
synthase was implemented. In addition to functioning
as a GPP synthase, the engineered enzyme was unable to
perform the sequential FPP synthesis reaction, that is
seen for the wild type (WT) S. cerevisiae FPP synthase
Erg20 enzyme, thus removing a potentially competing
pathway that had been identified as an important factor
limiting monoterpene titres [20]. In addition, the authors
reasoned that the fusion of the Erg20 enzyme and sabi-
nene synthase would help to direct GPP to the the
sabinene synthase to rapidly sequester GPP at its source.
Furthermore, the deletion of one Erg20 allele, thus
reducing the gene doses of WT Erg20 and shifting the
balance in favour of the overexpressed engineered Erg20
from a plasmid, resulted in a 340-fold improvement of
sabinene titre (17.5 mg/L) compared with the original
WT Erg20 (Table 1). In comparison to these relatively
low titres, Ignea et al. [21] had previously successfully
engineered a yeast system capable of producing cineole
on a much larger scale, eventually reaching titres of
>1000 mg/L. This was achieved using recyclable integra-
tion cassetes that facilitated unlimited sequential inte-
gration of genetic elements and was applied to the sterol
biosynthetic genes HMG2, ERG20 and IDI1.
Diversification of monoterpenes/
monoterpenoids
To date, the majority of studies have reported the con-
version of GPP to monoterpenes/monoterpenoids in a
single step, but much of the natural diversity is created by
subsequent tailoring by isomerisation or hydroxylation,Current Opinion in Chemical Biology 2016, 34:37–43 among others. For example, limonene is a key interme-
diate of the mint pathways (leading, among others, to the
valuable flavour and fragrance compounds originally de-
rived from spearmint and peppermint). Recent work
reported the use of a complementary cell-free synthetic
biology strategy for the production of these tailored
products using extracts from engineered E. coli containing
biosynthetic genes from Nicotiana tabacum, including a
double bond reductase (NtDBR), (–)-menthone:(–)-men-
thol reductase (MMR) and menthone:(+)-neomenthol
reductase (MNMR) pathways [22]. This one-pot bio-
catalytic approach suggests new opportunities for the
modular combination of reactions to generate libraries
of derived monoterpenes/monoterpenoids, for example,
for use in high-throughput screening for new functionali-
ties.
A particular strength of synthetic biology is the ability to
produce non-natural compounds by co-expression of
enzymes, sourced from a variety of different organisms,
in new combinations not found in nature. One recently
published example of this exploited the modularity of
class I and II diterpene synthases (diTPSs) by systemati-
cally co-expressing diTPSs in heterologous hosts. Ham-
berger and colleagues constructed a library of 51 diTPS
combinations, 41 of which were described as ‘new-to-
nature’, resulting in a significant increase in product
diversity [23]. Further efforts to improve diversity of
monoterpenes included the incorporation of non-natural
tailoring enzymes into pathways (e.g. cytochrome P450s
or glycosyltransferases). The inclusion of such ‘non-nat-
ural’ enzyme combinations could be successful in provid-
ing access to new chemical space [11]. For example, the
incorporation of a Mycobacterium sp. cytochrome P450 into
an engineered E. coli limonene producer resulted in the
production of perillyl alcohol.
Alternative efforts to improve monoterpene/monoterpe-
noid titres include the editing and optimization of
enzymes used in the biosynthetic pathways via directed
evolution strategies [24]. In this approach, mutant librar-
ies are created by systematically varying the specific
amino acid residues within an enzyme that are expected
to affect substrate specificity, product purity or catalytic
efficiency, and high-throughput screening and selection
identifies optimal variants, that produce the desired pro-
ducts faster and more selectively, sometimes even accept-
ing non-natural substrates not suitable for the original
native enzyme. Directed evolution for enzyme optimiza-
tion is important for monoterpene production, as mTS/Cs
invariably also produce multiple monoterpenes, in addi-
tion to the desired main product, which is not ideal for
commodity chemical production. Sequence analysis has
shown that even mTS/Cs sharing close sequence identity
can produce distinct monoterpene profiles [25,26]. The
rational engineering or directed evolution of mTS/C for
altered or cleaner product profiles is therefore a mainwww.sciencedirect.com
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biology. These approaches may also be exploited as a
means of introducing further diversity into monoterpene/
monoterpenoid production. The ability to alter the sub-
strate specificity of monoterpene synthases, such that
new suites of small, structurally diverse natural product
libraries may be obtained, alongside the ability to ‘re-
program’ monoterpene synthase activity may be of sig-
nificant interest to the fine chemical and pharmaceutical
industries.
Outlook for future pathway design
Establishing genetic parts needed for the production of
secondary metabolites, like monoterpenes/monoterpe-
noids, is the first challenge faced by synthetic biologists
and commonly tackled by computational tools [27].
Predicting bacterial terpene synthases is very challeng-
ing, but extensive HMM analysis of the Pfam [28]
database can be applied to identify new terpene
synthases [10] and test them in production systems
[29]. Once the monoterpene synthase of interest has
been identified, it must be brought into genomic con-
text by choosing the appropriate chassis, usually yeast
or E. coli. Other host organisms engineered for the
production of monoterpenoids include Corynebacterium
glutamicum [30] and Pseudomonas putida [31], which
were developed for the production of pinene and gera-
nic acid, respectively. In addition, the Gram-positive
bacterium Bacillus subtilis, which is already widely
used in biotechnological applications, has recently been
promoted as a potential platform for the general pro-
duction of terpenoids, although to date there are
no published instances of mTS/C production in this
species [32].
The next step is the design of intrinsic regulation within
the engineered biosynthetic gene cluster, where regu-
latory parts need to be selected carefully in order to
reach the maximal efficiency of the selected parts [33].
It has been demonstrated for limonene-producing E. coli
strains that production is highly dependent on the
number of plasmids per cell, which can be modulated
by changing the selective pressure using different anti-
biotics concentrations [11]. In yeast, inserting path-
ways on the chromosome has been shown to increase
diterpenoid production up to threefold, and similar
effects would be expected for monoterpenes/monoter-
penoids [23]. In addition, genomic insertion would help
in reducing biological variation, making the whole sys-
tem more productive, which was demonstrated  also in E.
coli, where a threefold increase of production levels was
observed for the tetraterpene, b-carotene [34]. With the
emergence of the CRISPR-Cas9 technology, genome
editing on a large scale has become more timely and
affordable [35,36]. This technology allows biosystems
engineers to insert de novo synthesized genes of up to
8 kbp and produce knock-outs of up to 18 kbp on thewww.sciencedirect.com E. coli chromosome [37–39]. Other production chassis,
such as S. cerevisiae [40], C. glutamicum [41] and Strepto-
myces sp. [42] can be CRISPR-Cas9 genome edited in a
similar fashion. Additionally, various conventional
methods of genome editing (using selection markers)
can be employed in Pseudomonas putida and many other
potential microbial production hosts [42]. The new
opportunities created by the CRISPR/Cas technology
have been strikingly demonstrated by engineering yeast
for the production of farnesol, a sesquiterpene, which
could not be produced if the pathway was encoded on a
plasmid [44].
For E. coli it has been demonstrated that limonene is
converted spontaneously to its toxic hydroperoxide form,
causing severe growth retardation [45]. A natural point
mutation in the gene for alkyl-hydroperoxidase (AhpC)
decreased the formation of limonene hydroperoxide,
resulting in improved limonene tolerance. Targeted ge-
nome editing will play a considerable role in engineering
tolerant strains for improved production. Another strategy
to overcome general cytotoxic effects of chemicals pro-
duced in a production host is the compartmentalization of
the pathway, thus reducing the active concentration and
intrinsic toxicity of the produced chemical or the pathway
intermediates. Suitable compartments that are being
explored for this purpose include peroxisomes in yeast
and proteinaceous micro-compartments in bacteria
[46,47].
Conclusion
The synthetic biology of monoterpene/monoterpenoid
production has already made substantial progress in re-
cent years, promising sustainable and economically viable
new routes to industrial-scale production of these valu-
able chemicals. However, this is only the beginning: in
the near future, we expect to see new computational tools
identifying even more genes to add to the monoterpene/
monoterpenoid diversification toolbox; advances in meta-
bolomics and proteomics that will more rapidly identify
bottlenecks in engineered biosynthetic pathways; prog-
ress in directed protein evolution that will increase prod-
uct purity and chemical diversity; and ever faster and
more robust genome editing techniques that will facilitate
the rapid and automated introduction and combinatorial
assembly of biosynthetic pathway variants into tailor-
made high-performance industrial chassis strains. To-
gether, these tools will enable a profound transformation
in the bio-industrial production of an increasingly diverse
range of monoterpenes and their derivatives.
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